ORIC Pharmaceuticals, Inc. (ORIC) Key Metrics
ORIC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.28B
- Enterprise value
- $1.12B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.6 10-yr median 2.1
- EV / EBITDA
- 0.1
- Dividend yield
- —
- Beta
- 0.98
ORIC key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsORIC valuation Price multiples at each fiscal year-end price.
ORIC returns How much profit the business earns on the capital it uses.
ORIC per-share figures Results divided by the shares outstanding at year-end.
ORIC financial health Debt, liquidity and how easily interest is covered.
ORIC efficiency & capital use Working capital cycle and where the cash goes.
ORIC valuation history
ORIC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ORIC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ORIC price vs earnings per share
ORIC key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $718.2M | $562.7M | $473.3M | $233.6M | $557.9M | $742.8M | — | — | — |
| Enterprise value | $448.2M | $309.9M | $275.4M | $39.4M | $322.9M | $449.7M | — | — | — |
| Price / book | 1.9 | 2.3 | 2.1 | 1.1 | 2.0 | 2.6 | — | — | — |
| Earnings yield | −18.0% | −22.7% | −21.3% | −38.2% | −13.9% | −9.9% | — | — | — |
| Free cash flow yield | −15.9% | −20.2% | −18.3% | −33.1% | −10.8% | −6.2% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $8.18 | $8.07 | $9.20 | $5.89 | $14.70 | $33.85 | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$1.47 | −$1.83 | −$1.96 | −$2.25 | −$2.05 | −$3.36 | −$0.90 | — | — |
| Operating cash flow per share | −$1.29 | −$1.62 | −$1.67 | −$1.89 | −$1.57 | −$2.06 | −$0.79 | — | — |
| Free cash flow per share | −$1.30 | −$1.63 | −$1.68 | −$1.95 | −$1.59 | −$2.09 | −$0.81 | — | — |
| Cash per share | $3.21 | $3.67 | $4.05 | $5.20 | $6.24 | $13.38 | $2.98 | — | — |
| Book value per share | $4.38 | $3.49 | $4.36 | $5.61 | $7.19 | $13.21 | $2.94 | — | — |
| Tangible book value per share | $4.38 | $3.49 | $4.36 | $5.61 | $7.19 | $13.21 | $2.94 | — | — |
| Capex per share | $0.01 | $0.02 | $0.02 | $0.05 | $0.02 | $0.03 | $0.03 | — | — |
| Debt per share | $0.13 | $0.05 | $0.20 | $0.31 | $0.05 | $0.02 | $0.02 | — | — |
| Shares outstanding | 87.8M | 69.7M | 51.5M | 39.7M | 38.0M | 21.9M | 29.9M | — | — |
| Change in shares outstanding | +25.9% | +35.5% | +29.7% | +4.5% | +73.0% | −26.6% | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −41.3% | −54.7% | −45.1% | −36.0% | −27.6% | −39.0% | −228.3% | — | −85.6% |
| Return on invested capital (ROIC) | −215.7% | — | −322.4% | −219.4% | −359.7% | — | — | — | — |
| Return on assets (ROA) | −37.8% | −48.4% | −39.9% | −32.5% | −26.0% | −37.5% | −38.2% | −55.7% | −73.4% |
| Return on tangible assets | −31.5% | −46.6% | −39.5% | −35.6% | −26.0% | −24.7% | −28.6% | −45.7% | −73.4% |
| Financial health | |||||||||
| Total debt | $11.6M | $3.2M | $10.2M | $12.1M | $1.9M | $546,000 | $495,000 | — | — |
| Cash & short-term investments | $281.5M | $256.0M | $208.2M | $206.3M | $237.0M | $293.6M | $89.2M | $42.6M | $25.8M |
| Net debt | −$269.9M | −$252.8M | −$198.0M | −$194.2M | −$235.1M | −$293.1M | −$88.7M | −$42.6M | −$25.8M |
| Debt / equity | 0.03 | 0.01 | 0.05 | 0.05 | 0.01 | 0.00 | 0.01 | — | — |
| Debt / assets | 0.03 | 0.01 | 0.04 | 0.05 | 0.01 | 0.00 | 0.01 | — | — |
| Current ratio | 14.13 | 10.56 | 10.39 | 13.68 | 15.87 | 32.96 | 16.81 | 16.84 | 10.20 |
| Quick ratio | 14.13 | 10.56 | 10.39 | 13.68 | 15.87 | 32.96 | 16.81 | 16.84 | 10.20 |
| Interest coverage | — | — | — | -34.7 | -559.4 | -242.4 | -16.9 | -22.2 | — |
| Working capital | $268.0M | $237.4M | $192.1M | $195.1M | $225.4M | $287.7M | $84.6M | $41.1M | $24.0M |
| Invested capital | $114.4M | −$9.7M | $26.1M | $28.2M | $37.9M | −$3.3M | −$690,000 | −$107.1M | −$93,000 |
| Tangible asset value | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M | $289.8M | $88.0M | −$64.4M | $25.7M |
| Net current asset value | $261.8M | $231.2M | $182.0M | $182.4M | $214.9M | $287.5M | $83.9M | −$67.4M | $22.3M |
| Graham net-net per share | $2.90 | $3.23 | $3.45 | $4.50 | $5.57 | $12.96 | $2.78 | — | — |
| Capital allocation | |||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | — |
| Capex / depreciation | 0.58 | 1.07 | 0.82 | 2.15 | 1.05 | 0.69 | 0.75 | 0.58 | 0.54 |
| Efficiency | |||||||||
| Days payables outstanding | 803.6 | 410.8 | 400.4 | 605.7 | 537.7 | 171.0 | 109.1 | 281.1 | 381.2 |
| Payables turnover | 0.45 | 0.89 | 0.91 | 0.60 | 0.68 | 2.13 | 3.34 | 1.30 | 0.96 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $2.7M | $1.2M | $1.1M | $1.6M | $1.3M | $454,500 | $299,000 | $693,000 | $940,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ORIC's annual financial statements (latest annual report filed February 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ORIC valuation and financial ratios
ORIC Pharmaceuticals earned a return on equity of −41.3% and a return on invested capital of −215.7% in fiscal 2025. It ended the year with $11.6 million of debt and $281.5 million in cash and short-term investments, a net cash position of $269.9 million.
See the ORIC income statement, the ORIC chart for price history, or the ORIC stock overview for the latest quote and news.
ORIC key metrics FAQ
What is ORIC Pharmaceuticals's return on equity?
ORIC Pharmaceuticals's return on equity (ROE) was −41.3% in fiscal 2025: net income of -$129.5 million on average shareholders' equity of $313.7 million.
What is ORIC Pharmaceuticals's ROIC?
ORIC Pharmaceuticals's return on invested capital was −215.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does ORIC Pharmaceuticals have?
ORIC Pharmaceuticals had total debt of $11.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is ORIC Pharmaceuticals's free cash flow yield?
ORIC Pharmaceuticals generated -$114.1 million of free cash flow in fiscal 2025, a free cash flow yield of −15.9% on its market value at year-end ($718.2 million).
What is ORIC Pharmaceuticals's current ratio?
ORIC Pharmaceuticals's current ratio was 14.13 at the end of fiscal 2025: current assets were 14.13 times current liabilities.